An early clinical trial has revealed promising results for patients with advanced lung cancer. One-third of the participants experienced a reduction in tumor size, a significant finding that is leading to larger ongoing trials.
The trial specifically targeted individuals with advanced non-small-cell lung cancer who had previously undergone standard treatments, such as chemotherapy. The results were published in the New England Journal of Medicine.
The trial highlights a pancreatic cancer drug that has shown effectiveness against non-small-cell lung cancer, the most prevalent form of the disease. This information was gathered and reported by Pascal Pochard-Casabianca, with images via AFP, and was made public on September 2, 2026, at 5:17 PM EDT.

The Future of MAHA in American Health Politics
Insulin Cost Caps Gaining Support Amid Rising Prices
A Personal Journey Through Encephalitis
Low-Cost Medication May Benefit Stroke Survivors
The Complex Debate Over Kratom Use in the U.S.
Florida’s Struggle with Dengue Fever and AI Solutions